Matt Martin, PharmD, BCSCP, explores current developments in the peptide space and what pharmacists need to know amid FDA decision-making processes.
Commentary|Articles|October 17, 2026
FAQ: Scaling Pharmacy Services Through GLP-1 Care | NCPA 2026
Nicole Pezzino, PharmD, BCACP, BC-ADM, CDCES, details how pharmacies can utilize the booming GLP-1 medication class for greater revenue opportunities.
Advertisement
Advertisement
With new formulations, expanding indications, and a flood of information on social media, the GLP-1 landscape is evolving rapidly, and pharmacies are well-positioned to help patients understand the evidence, all while boosting revenue and community outcomes.
Related to this article
Detailed phase 3 data show retatrutide lowered body weight and A1C over 80 weeks for patients with diabetes and obesity.
In a rapidly evolving diabetes and obesity management landscape, Brian Smith, PharmD, discusses approaches that are helping patients maximize their outcomes on GLP-1 therapy.
In this episode, our hosts examine the expanding role of incretin therapies in children and adolescents with obesity and type 2 diabetes.
GLP-1 adherence requires integrated care teams, administrative technology, and proactive clinical support to tackle complex challenges.
Orforglipron lowered A1C and body weight more than oral semaglutide 25 mg at 52 weeks, but the estimate comes from an indirect comparison.
Sara Hover, RPh, FAARM, explains how these products are putting pharmacists at the center of safety and evidence evaluations one patient at a time.
Lara Zakaria, PharmD, MS, CNS, FMCP, discusses her perspectives regarding the emergence of wearable technology among community pharmacy patients.
Advertisement
Advertisement